Alzheon is a brand that is dedicated to developing groundbreaking medicines for patients afflicted with Alzheimer's disease and other neurological disorders. They have a strong focus on preserving future memories and aim to introduce the first oral treatment capable of slowing down or halting the progression of Alzheimer's disease. Alzheon's product, ALZ-801 (valiltramiprosate), is currently in Phase 3 testing and is the only oral anti-amyloid disease-modifying treatment being evaluated for Alzheimer's disease.

Based on their pioneering precision medicine approach, Alzheon is initially targeting the highest-risk patients who possess two copies of the APOE4 gene, as they are predicted to benefit the most from this treatment. With a well-tolerated safety profile and consistent positive data, Alzheon is poised to bring ALZ-801 to market and make a significant impact in the fight against Alzheimer's disease